Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 29 2022 - 05:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its
charter)
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On June 29, 2022, ADC Therapeutics SA (the “Company”)
announced that the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination
with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first arm of the LOTIS-7 open-label,
multi-center, multi-arm Phase 1b trial will evaluate the safety and activity of ZYNLONTA in combination with polatuzumab vedotin in patients
with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular
lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma. The trial will include multiple arms in two parts –
a dose escalation part and a dose expansion part.
INCORPORATION BY REFERENCE
This Report on Form 6-K shall be deemed to be incorporated
by reference into the registration statements on Form F-3 (Registration Nos. 333-256686 and 333-256807) of ADC Therapeutics SA and to
be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed
or furnished.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ADC Therapeutics SA |
Date: June 29, 2022 |
|
|
|
|
By: |
/s/ Michael Forer |
|
Name: |
Michael Forer |
|
Title: |
Executive Vice President and General Counsel |
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2023 to Mar 2024